ArticleAntibiotics (Basel, Switzerland)2020
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Jinghua Weikang capsule forFrontiers in pharmacology · 2022Pooled it
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Characterization ofJournal of bacteriology · 2026Article
- Correlation versus causation:mSphere · 2026Article
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- The Role ofInternational journal of molecular sciences · 2025Review
- The impact of the flagellar protein genemSphere · 2025Article
- Review
- Optimization ofInternational journal of molecular sciences · 2024Article
- Article
- Subinhibitory concentrations of antibiotics affect development and parameters ofFrontiers in pharmacology · 2024Article
- Treatment ofHeliyon · 2023Review
- Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents.Archives of microbiology · 2023Review
- Biofilm ofAntibiotics (Basel, Switzerland) · 2023Review
- Review
- Research on antibiotic resistance inFrontiers in microbiology · 2023Article
- Armeniaspirol A: a novel anti-Helicobacter pylori agent.Microbial biotechnology · 2022Article
- Detection and Treatment ofGastroenterology research and practice · 2022Review
- Review
- Biofilm Formation ofFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.